Skip to main content
VRCA logo

VRCA · Verrica Pharmaceuticals Inc. · Documents

Track VRCA — free
$3.56 -0.16 (-4.30%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Market Cap
$61.16M
Shares
17.18M
Volume · Nov 13 18.68K Avg daily vol (3M) 72.22K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $35.58M up 370.2% 10-K filed Mar 11, 2026 Quarterly report New FY2026 Q3 Revenue $6.91M down 51.8% 10-Q filed Nov 13, 2026 Latest results New Record YCANTH revenue reaches $5.7 million as COVE-2 enrollment completes 8-K filed Nov 12, 2026 Earnings call New Q3 2026 earnings call Held Nov 12, 2026
2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash of $14.4 million raises substantial going-concern doubt

Verrica Pharmaceuticals reported $14.4 million cash as of September 30, 2026 and substantial doubt about continuing as a going concern within one year. Nine-month YCANTH product revenue rose to $15.1 million from $11.6 million.

Revenue $6.91M ▼ 51.8% Net loss $12.41M Diluted EPS -$0.58
Read from the MD&A section
3 source passages
As of September 30, 2026, we had cash of $14.4 million. Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued. Product revenue, net was $15.1 million for the nine months ended September 30, 2026, compared to $11.6 million for the nine months ended September 30, 2025. Open the document at this passage
Nov 12
Earnings call
Wycanth revenue reached $5.7 million as trials advanced

Verrica Pharmaceuticals reported U.S. Wycanth product revenue of $5.7 million in the third quarter of 2026. One Phase III trial completed enrollment, the second exceeded 50% enrollment, and readouts are expected in the first quarter of 2027 and mid-2027.

5 source passages
U.S. net Wycanth product revenue was $5.7 million in the third quarter of 2026. In August, we announced the completion of enrollment in COVID-2, the first pivotal Phase III trial, after an interim analysis confirmed that no additional patients were recommended for enrollment. And in late August, we announced that enrollment has exceeded 50% of its current target. We expect top-line data from COVID-2 to be available in the first quarter of 2027. We expect top-line data from this trial to be available by mid-2027. Open the document at this passage
Nov 12
Current report 8-K
Record YCANTH revenue reaches $5.7 million as COVE-2 enrollment completes

Verrica Pharmaceuticals Inc. reported record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 57.9% year-over-year. COVE-2 enrollment is complete, with topline data expected in Q1 2027; COVE-3 enrollment exceeds 50%, with topline data expected in mid-2027.

Financial results
2 source passages
During the third quarter, the Company recorded YCANTH net product revenue of $5.7 million, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million. On August 27, 2026, the Company announced completion of enrollment in the first pivotal Phase 3 trial (COVE-2) studying YCANTH for the treatment of common warts and greater than 50% enrollment in the second pivotal Phase 3 trial (COVE-3). Topline data readouts for the trials are expected in the first quarter of 2027 and mid-2027, respectively. Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $5.86M ▼ 53.8% Net loss $13.15M Diluted EPS -$0.62
May 12
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $5.02M ▲ 46.1% Net loss $9.68M Diluted EPS -$0.45
Apr 20
Proxy statement DEF 14A Meeting Jun 5, 2026
Proxy statement AI summary on its way
Mar 11
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $35.58M ▲ 370.2% Net loss $17.89M Diluted EPS -$1.68
2025
Mar 11
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $7.57M ▲ 47.7% Net loss $76.58M Diluted EPS -$1.48
2024
Showing 1–50 of 153 documents
Key facts CIK 1660334 CUSIP 92511W207 13F (30d) 46 filings 25 filers Visit website Investor relations